Zydus Lifesciences Share Price: 25.7% CAGR in 3 Years as the Ahmedabad Drug Maker Tops Lupin
- November 11, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Zydus Lifesciences Share Price: 25.7% CAGR in 3 Years as the Ahmedabad Drug Maker Tops Lupin
Zydus Lifesciences previous close Rs 1,215.90. 3-year CAGR 25.7%. Up 2.0x since 9 Nov 2023. ROE 15.10%. Market cap Rs 1,21,002 crore.
Quick Answer
The Zydus Lifesciences share price closed at Rs 1,215.90 on 9 November 2026, a compounded annual return of 25.7% over three years. That compares with Lupin at 18.9% and Gland Pharma at 27.0%. The company has a market cap of Rs 1,21,002 crore and a P/E of 28.13 against an industry P/E of 40.13.
The Zydus Lifesciences share price has almost doubled in three years, and that has made Zydus Lifesciences one of the better performers among large Indian drug makers. The Ahmedabad-based company, earlier known as Cadila Healthcare, sells generic medicines, specialty drugs and vaccines.
This article compares that run with Lupin and Gland Pharma. We calculate the three-year CAGR for all three and set the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Zydus Lifesciences Share Price Returned in 3 Years?
The Zydus Lifesciences stock closed at Rs 612.45 on 9 November 2023 and at Rs 1,215.90 on 9 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.99 lakh, which is a CAGR of 25.7%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Zydus Lifesciences can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Zydus Lifesciences share price has also been supported by a strong Indian prescription business, steady generic exports to the United States and a widening pipeline of complex products.
Zydus Lifesciences vs Lupin and Gland Pharma: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 9 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 9 November 2026.
| Company | Close on 9 Nov 2023 | Previous close (9 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Gland Pharma | Rs 1,612.65 | Rs 3,302.40 | 2.0x | 27.0% |
| Zydus Lifesciences | Rs 612.45 | Rs 1,215.90 | 2.0x | 25.7% |
| Lupin | Rs 1,204.55 | Rs 2,025.00 | 1.7x | 18.9% |
The Zydus Lifesciences stock ranks second of the three at 25.7%. It sits ahead of Lupin (18.9%). The company ahead is Gland Pharma (27.0%). Gland Pharma finished slightly ahead of Zydus, with Lupin in third place. Zydus is the largest of the three by market cap, so its yearly return came on a bigger base of capital.
Look at the Zydus Lifesciences share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Zydus Lifesciences | Rs 1,21,002 crore | 28.13 | 40.13 | 15.10% | 0.50 |
| Lupin | Rs 92,007 crore | 17.62 | 40.13 | 21.65% | 0.26 |
| Gland Pharma | Rs 54,476 crore | 44.08 | 40.13 | 11.57% | 0.02 |
By market cap, Zydus Lifesciences is the largest of the group at Rs 1,21,002 crore, which gives it the scale advantage over Lupin, Gland Pharma. On earnings, Zydus Lifesciences shares trade at a P/E of 28.13 against an industry P/E of 40.13, a discount of about 30% to the sector, which leaves room if earnings keep growing. Peer multiples are Lupin at 17.62 and Gland Pharma at 44.08.
Return on equity is 15.10% for the Zydus Lifesciences stock, which ranks second among the three, and debt to equity stands at 0.50. Trailing EPS is Rs 43.13. Diversified drug makers are valued on the breadth of their product baskets and the success of new launches, so the P/E should be read next to return on equity and the debt position.
What Is Driving the Zydus Lifesciences Stock?
Zydus Lifesciences earns revenue from branded medicines in India, generic products in the United States and a growing set of specialty and biologic products. It also works on vaccines, and its research activity covers new chemical entities and complex generics.
The company has expanded its presence in India through chronic therapy brands, which bring recurring prescriptions. Regulatory approvals for complex products abroad add to growth, although timing is uncertain.
Followers of the Zydus Lifesciences share price usually track launches in the United States, growth of the India business, regulatory inspections and progress in specialty and biologic programmes.
How the Established Players Stack Up
Lupin is a Mumbai-based pharma company with strength in respiratory, cardiac and anti-infective medicines and a large export business. It compounded at 18.9% a year, on a market cap of Rs 92,007 crore and an ROE of 21.65%.
Gland Pharma is a Hyderabad-based maker of injectable medicines that works with partners across regulated markets. It compounded at 27.0% a year, on a market cap of Rs 54,476 crore and an ROE of 11.57%.
What Should Investors Track Next?
Three things are worth watching on the Zydus Lifesciences share price. First, new launches in the United States. Second, the growth of the India branded business. Third, progress in specialty and biologic products.
At a P/E of 28, the stock trades below the industry P/E of 40, and its debt to equity of 0.50 is low. That leaves room if earnings keep growing.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Zydus Lifesciences stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Zydus Lifesciences share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Zydus Lifesciences share price and compare pharma stocks live.
A Diversified Drug Maker Trading Below Its Sector Multiple
The Zydus Lifesciences share price compounded at 25.7% a year over three years, ahead of Lupin at 18.9% and behind Gland Pharma at 27.0%. Its P/E of 28.13 is below the industry level.
Lupin brings a higher ROE, while Gland Pharma brings an injectables focus and a smaller base. The choice depends on whether you prefer breadth or specialisation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Zydus Lifesciences share price today?
Ans. Zydus Lifesciences closed at Rs 1,215.90 on 9 November 2026, according to NSE data. It has a market cap of Rs 1,21,002 crore and a P/E of 28.13. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Zydus Lifesciences stock?
Ans. Zydus Lifesciences delivered a price CAGR of 25.7% over three years, moving from Rs 612.45 on 9 November 2023 to Rs 1,215.90 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Zydus Lifesciences better than Lupin?
Ans. Zydus Lifesciences delivered a higher three-year CAGR at 25.7% than Lupin at 18.9%. Zydus is larger by market cap at Rs 1,21,002 crore against Rs 92,007 crore, while Lupin has a higher ROE at 21.65% against 15.10% and a lower P/E of 17.62 against 28.13. The better choice depends on your view of each business.
What does Zydus Lifesciences do?
Ans. Zydus Lifesciences, earlier known as Cadila Healthcare, is an Ahmedabad-based drug maker with generic, specialty and vaccine businesses in India and abroad.
Is the Zydus Lifesciences stock debt free?
Ans. The debt to equity ratio of the Zydus Lifesciences stock is 0.50 and its return on equity is 15.10%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Zydus Lifesciences expensive compared with the industry?
Ans. Zydus Lifesciences trades at a P/E of 28.13 against an industry P/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Gland Pharma delivered the highest three-year CAGR at 27.0%, followed by Zydus Lifesciences at 25.7%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.